<SEC-DOCUMENT>0001140361-25-040675.txt : 20251106
<SEC-HEADER>0001140361-25-040675.hdr.sgml : 20251106
<ACCEPTANCE-DATETIME>20251106082536
ACCESSION NUMBER:		0001140361-25-040675
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251106
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251106
DATE AS OF CHANGE:		20251106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Opus Genetics, Inc.
		CENTRAL INDEX KEY:			0001228627
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				113516358
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34079
		FILM NUMBER:		251456328

	BUSINESS ADDRESS:	
		STREET 1:		8 DAVIS DRIVE
		STREET 2:		SUITE 220
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		248-681-9815

	MAIL ADDRESS:	
		STREET 1:		8 DAVIS DRIVE
		STREET 2:		SUITE 220
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ocuphire Pharma, Inc.
		DATE OF NAME CHANGE:	20201109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REXAHN PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20050516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORPORATE ROAD SHOW DOT COM INC
		DATE OF NAME CHANGE:	20030423
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ny20058362x4_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ird="http://opusgtx.com/20251106" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_3e7c73bae3b1489fb51668a095f5478b" contextRef="c20251106to20251106" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_3215b7ca6c38423caa07ebc5c88b135d" contextRef="c20251106to20251106">0001228627</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_7cc84b12df5a4adaa324db56a05fc359" contextRef="c20251106to20251106">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ird-20251106.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20251106to20251106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-06</xbrli:startDate><xbrli:endDate>2025-11-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
<div>UNITED STATES</div>
</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_be0e0839da414ddf904016b5277f2d76" contextRef="c20251106to20251106">8-K</ix:nonNumeric></div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_5f47c948e66549118cfd716db60a6206" contextRef="c20251106to20251106" format="ixt:date-monthname-day-year-en">November 6, 2025</ix:nonNumeric></div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_f5789a09ced34601a2b51402b10275f8" contextRef="c20251106to20251106">Opus Genetics, Inc.</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Exact name of registrant as specified in its charter)</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_d891607bb9364933a887f8861733eebc" contextRef="c20251106to20251106" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_aca7f8db8a3748b89b592c6be1cf3b52" contextRef="c20251106to20251106">001-34079</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_946799eb84384ab29c72baf0210f20b3" contextRef="c20251106to20251106">11-3516358</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(State or other jurisdiction of incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Commission File Number)</div>
          </td>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 67%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_00cfb7a941b042308c064a65597562e1" contextRef="c20251106to20251106">8 Davis Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_9b81b1e629a44e488a1227e728c2fec9" contextRef="c20251106to20251106">Suite 220</ix:nonNumeric></div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_b76bd224cd1c4a458dfefb002a1b4879" contextRef="c20251106to20251106">Durham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_df8dee08f58048ba92b15d95b11a8cb0" contextRef="c20251106to20251106">NC</ix:nonNumeric></div>
          </td>

    <td style="width: 33%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_f6f0a65daf6d4c8ab62de7a302dfafeb" contextRef="c20251106to20251106">27713</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 67%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Address of principal executive offices)</div>
          </td>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_afb9c2a127b94d76a54e386a79a8f644" contextRef="c20251106to20251106">248</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_9678e496698342cca655d4a36e9a2859" contextRef="c20251106to20251106">957-9024</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Registrant&#8217;s telephone number, including area code)</div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">N/A</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Former name or former address, if changed since last report)</div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top;"> <ix:nonNumeric name="dei:WrittenCommunications" id="Fact_174ce4d8e1be44aab65de116328e93bc" contextRef="c20251106to20251106" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 18pt; vertical-align: top;">&#160;</td>

    <td style="width: auto; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 18pt; vertical-align: top;"> <ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_2aa9ece918464f82a931fede3c5517af" contextRef="c20251106to20251106" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 18pt; vertical-align: top;">&#160;</td>

    <td style="width: auto; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 18pt; vertical-align: top;"> <ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_6b48ce8639734d66afc14022ec875b8b" contextRef="c20251106to20251106" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>

  <tr>

    <td style="width: 18pt; vertical-align: top;">&#160;</td>

    <td style="width: auto; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 18pt; vertical-align: top;"> <ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_5e5a3cfdeb354968b1cb719b9b987f77" contextRef="c20251106to20251106" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 40.02%; vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 18.21%; vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Trading Symbol(s)</div>
          </td>

    <td style="width: 41.77%; vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.02%; vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_612bdfb951274f06af3038330de37992" contextRef="c20251106to20251106">Common Stock, $0.0001 par value per share</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 18.21%; vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_4a0c6dc3ecda43989bed020313b8e665" contextRef="c20251106to20251106">IRD</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 41.77%; vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_7cc84b12df5a4adaa324db56a05fc359">The Nasdaq Stock Market LLC</span><br/>
            </div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or
      Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_87d3f6b5bd1044a190584812a8d359cd" contextRef="c20251106to20251106" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
<div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;
      </div>
<hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#8201;7.01</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Regulation FD Disclosure.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On November 6, 2025, Opus Genetics, Inc. (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Company</span></span>&#8221;) issued
      a press release announcing a $23 million registered direct offering (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Offering</span></span>&#8221;), a copy of which is furnished as Exhibit 99.1 hereto.</div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Also on November 6, 2025, the Company issued a press release announcing the successful completion of a Type B Regenerative Medicine Advanced Therapy (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">RMAT</span></span>&#8221;) meeting with the U.S. Food and Drug Administration (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">FDA</span></span>&#8221;)
      regarding OPGx-LCA5, its gene therapy candidate for Leber congenital amaurosis (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">LCA</span></span>&#8221;) caused by mutations in the LCA5 gene, a copy of which is furnished as
      Exhibit 99.2 hereto.</div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of
      Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Exchange Act</span></span>&#8221;), and is not incorporated by reference into any of the Company&#8217;s filings
      under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#8201;8.01</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Other Events.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company announced the successful completion of a Type B RMAT meeting with the FDA regarding OPGx-LCA5, its gene therapy candidate for LCA caused by
      mutations in the LCA5 gene. The meeting provided constructive feedback from the FDA on key elements of the Company&#8217;s registration strategy, including Chemistry, Manufacturing and Controls (CMC) and the pivotal trial design. The FDA acknowledged the
      significant unmet medical need for individuals with LCA5-related blindness and reaffirmed its commitment to regulatory flexibility for rare genetic diseases. To date in the Phase 1/2 portion of the trial, six late-stage participants have been treated
      with OPGx-LCA5, all of whom have experienced clinically meaningful improvements in vision, providing evidence of biological activity with the potential for functional restoration of vision in individuals with advanced disease.</div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company will incorporate the FDA&#8217;s feedback into its updated clinical development and CMC plans for the Phase 3 portion of the study, which will include
      enrolling as few as eight participants in a single-arm, 12-month study utilizing an adaptive design and provides flexibility regarding endpoints and number of participants, reflective of LCA5 as a rare condition with an urgent medical need.</div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company expects the Phase 3 portion of the trial will include a run-in period prior to dosing to evaluate the natural history of each participant to serve
      as their own control in the study. The Company is actively identifying patients for this segment and has enrolled the first participant for ongoing disease monitoring. Efficacy and safety will be assessed using measures such as visual acuity,
      full-field stimulus testing, microperimetry, and the Multi-Luminance Orientation and Mobility Test (MLoMT). Following availability of validated clinical drug supply manufactured with the intended commercial processes, dosing with OPGx-LCA5 is
      anticipated in the second half of 2026, with topline clinical data expected approximately one year later.</div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2025, the FDA introduced the Rare Disease Evidence Principles (RDEP) review process to facilitate the approval of drugs intended to treat rare
      diseases with very small patient populations, a significant unmet medical need and a known genetic defect that is the major driver of the pathophysiology. With a patient population of fewer than 1,000 individuals, the Company believes that its LCA5
      program meets the eligibility criteria for the RDEP process and plans to submit an application.</div>

    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Including expected proceeds from the Offering and based on current operating plans, the Company expects its cash resources will fund operations into the
      second half of 2027, excluding any potential proceeds from callable warrants or future milestone payments.</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#8201;9.01</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 5%; vertical-align: bottom; white-space: nowrap;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">Exhibit</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">No.</div>
          </td>

    <td style="width: 95%; vertical-align: bottom; white-space: nowrap;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">Description</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: middle;">&#160;</td>

    <td style="width: 95%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20058362x4_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 95%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Press Release of Opus Genetics, Inc., dated November 6, 2025.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: middle;">&#160;</td>

    <td style="width: 95%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20058362x4_ex99-2.htm">99.2</a></div>
          </td>

    <td style="width: 95%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Press Release of Opus Genetics, Inc., dated November 6, 2025.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 95%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
          </td>

    <td style="width: 95%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">This Current Report on Form 8-K contains forward-looking statements within the
        meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and
        Section 21E of the Exchange Act. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, the intended use of
        proceeds of the Offering and other statements relating to the Offering. In some cases, you can identify forward-looking statements by terms such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;approach,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;could,&#8221; &#8220;designed&#8221;, &#8220;estimate,&#8221;
        &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;look,&#8221; &#8220;may,&#8221; &#8220;mission,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;pursue,&#8221; &#8220;should,&#8221;, &#8220;strive&#8221;, &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative thereof and similar words and expressions. Forward-looking
        statements are based on management&#8217;s current expectations, beliefs and assumptions and on information currently available to the Company. Such statements are neither promises nor guarantees, and involve a number of known and unknown risks,
        uncertainties and assumptions. Actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, without limitation, risks and uncertainties associated with the consummation of
        the Offering, uncertainties related to market conditions, the satisfaction of customary closing conditions, the completion of the Offering on the anticipated terms or at all, general economic conditions and other risks identified from time to time
        in the reports the Company files with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC&#8217;s website
        at </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">www.sec.gov</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The forward-looking statements in this
        Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update or revise any of the statements. The Company&#8217;s business is subject to substantial risks and uncertainties,
        including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</span></div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td style="vertical-align: bottom;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OPUS GENETICS, INC.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

    <td style="width: 5%; vertical-align: middle;">&#160;</td>

    <td style="width: 45%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: November 6, 2025</div>
          </td>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
          </td>

    <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Dr. George Magrath</div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name:</div>
          </td>

    <td style="width: 45%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dr. George Magrath</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title:</div>
          </td>

    <td style="width: 45%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Executive Officer</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/> </div>

  </div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ny20058362x4_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadrdige Financial
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right; color: #EE0000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="color: rgb(0, 0, 0);">Exhibit 99.1</font></div>
  <div><br>
  </div>
  <div style="text-align: left; color: rgb(238, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">FINAL FOR GLOBENEWSWIRE</div>
  <div><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">Opus Genetics Announces $23 Million Registered Direct Offering</div>
  <div><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">- Financing led by Perceptive Advisors and Balyasny Asset Management -</div>
  <div><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">- Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs -</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">RESEARCH TRIANGLE PARK, N.C. &#8211; November 6, 2025 - <font style="color: rgb(70, 120, 133);"><u>Opus Genetics, Inc</u></font>. (Nasdaq: IRD) (the &#8220;Company&#8221; or
    &#8220;Opus Genetics&#8221;) a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs)<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </font>small molecule
    therapies for other ophthalmic disorders, today announced that it has entered into a securities purchase agreement to sell securities in a registered direct offering (the &#8220;offering&#8221;) for gross proceeds of approximately $23 million, before deducting
    offering expenses. The financing, which included new and existing institutional investors, was led by Perceptive Advisors and Balyasny Asset Management, with participation by Nantahala Capital.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Opus intends to use the net proceeds to advance its LCA5 and BEST-1 gene therapy clinical programs, as well as for working capital and general corporate
    purposes. Including expected proceeds from this offering and based on current operating plans, the Company expects its cash resources will fund operations into the second half of 2027, excluding any potential proceeds from callable warrants or future
    milestone payments.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;We appreciate the support of these respected healthcare investors, which reflects strong confidence in our clinical pipeline,&#8221; said George Magrath, M.D., Chief
    Executive Officer, Opus Genetics. &#8220;Following the successful outcome of our U.S. Food and Drug Administration (FDA) meeting for OPGx-LCA5, this financing positions us to advance our LCA5 and BEST-1 programs with the ultimate goal of restoring vision and
    preventing blindness in patients with inherited retinal diseases.&#8221;</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the offering, Opus is selling an aggregate of 3,827,751 shares of its common stock at a price of $2.09 per share and, in lieu of common stock to certain
    investors, pre-funded warrants to purchase up to an aggregate of 7,177,033 shares of common stock at a purchase price of $2.0899 per pre-funded warrant. Each pre-funded warrant has an exercise price of $0.0001 per share of common stock, will be
    immediately exercisable and may be exercised at any time until exercised in full. The offering is expected to close on November 7, 2025, subject to customary closing conditions. Sidley Austin LLP served as counsel to Opus in connection with the
    transaction. The Company did not use a placement agent in connection with the offering.</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The offering, including the shares of common stock issuable from time to time upon exercise of the pre-funded warrants, is being made pursuant to an effective
    shelf registration statement on Form S-3 (File No. 333-276462) filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on January 10, 2024 and declared effective by the SEC on January 23, 2024. The offering is being made only by means of a
    prospectus supplement and accompanying prospectus, which form a part of the registration statement. Copies of the prospectus supplement and accompanying prospectus will be filed with the SEC and will be available free of charge on the SEC&#8217;s website at
    <font style="color: rgb(70, 120, 133);"><u>www.sec.gov</u></font>.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any
    sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Opus Genetics</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule
    therapies for other ophthalmic disorders. The Company&#8217;s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy
    candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a
    partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information,
    visit <font style="color: rgb(70, 120, 133);"><u>www.opusgtx.com</u></font>.</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Forward Looking Statements</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but
    are not limited to, statements related to cash runway, the clinical development, clinical results, preclinical data and future plans for Phentolamine Ophthalmic Solution 0.75%, OPGx-LCA5, OPGx-BEST1, RDH12 and earlier stage programs, and expectations
    regarding us, our business prospects and our results of operations, and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from
    those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading &#8220;Risk Factors&#8221; included in our Annual Report on Form 10-K for the fiscal
    year ended December 31, 2024 and in our other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based
    upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of
    various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;aim,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
    &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to
    reflect events or circumstances that might subsequently arise.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contacts:</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Investors</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Jenny Kobin</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Remy Bernarda</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">IR Advisory Solutions</div>
  <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(70, 120, 133);"><u>ir@opusgtx.com</u></div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Media</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Kimberly Ha</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">KKH Advisors</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">917-291-5744</div>
  <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(70, 120, 133);"><u>kimberly.ha@kkhadvisors.com</u></div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Source: Opus Genetics, Inc.</div>
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ny20058362x4_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadrdige Financial
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 99.2</div>
  <div><br>
  </div>
  <div style="text-align: left; color: rgb(238, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"><u>FINAL FOR GLOBENEWSWIRE</u></div>
  <div><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal
    Disease</div>
  <div><br>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2ec5b5f0ba98442b8b978623cbdc50e3">

      <tr>
        <td style="width: 18pt;"><br>
        </td>
        <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
        <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z430fb6a0ad8d423a9cc65e5af8fa03e0">

      <tr>
        <td style="width: 18pt;"><br>
        </td>
        <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
        <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">First participant enrolled in run-in period for planned adaptive Phase 3 trial</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5dc3524806984ba5b70ae671a9636a5a">

      <tr>
        <td style="width: 18pt;"><br>
        </td>
        <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
        <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Company intends to apply for the FDA&#8217;s new Rare Disease Evidence Principles (RDEP) review process</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbf77665015184848aad7d878563df275">

      <tr>
        <td style="width: 18pt;"><br>
        </td>
        <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
        <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">OPGx-LCA5 has the potential to be the first gene therapy and one-time treatment for Leber congenital amaurosis (LCA) type 5</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0bd6cb96411641f4aa74c31a2cfa86f4">

      <tr>
        <td style="width: 18pt;"><br>
        </td>
        <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
        <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Recent $23 million financing led by Perceptive Advisors and Balyasny Asset Management to advance LCA5 and BEST1 programs and fund current operating plans into second half
            of 2027</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">RESEARCH TRIANGLE PARK, N.C. - November 6, 2025 - <font style="color: rgb(70, 120, 133);"><u>Opus Genetics, Inc</u></font>. (Nasdaq: IRD) (the &#8220;Company&#8221; or
    &#8220;Opus Genetics&#8221;), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, today announced the successful completion of a Type B Regenerative
    Medicine Advanced Therapy (RMAT) meeting with the U.S. Food and Drug Administration (FDA) regarding OPGx-LCA5, its gene therapy candidate for Leber congenital amaurosis (LCA) caused by mutations in the LCA5 gene.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The meeting provided constructive feedback from the FDA on key elements of Opus&#8217;s registration strategy, including Chemistry, Manufacturing and Controls (CMC),
    and the pivotal trial design. The FDA acknowledged the significant unmet medical need for individuals with LCA5-related blindness and reaffirmed its commitment to regulatory flexibility for rare genetic diseases.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;The FDA&#8217;s guidance provides confidence in our path to approval for OPGx-LCA5,&#8221; said George Magrath, M.D., Chief Executive Officer, Opus Genetics. &#8220;Importantly,
    we expect to be able to advance our ongoing trial using an adaptive design that includes a Phase 3 portion which will avoid the requirement for a separate registrational trial. Given the severe nature of the disease, we are actively identifying
    patients who may qualify for the Phase 3 and enrolling them into the planned run-in period to monitor their disease. This productive RMAT interaction represents an important milestone as we continue working closely with the FDA to bring sight-restoring
    gene therapies to patients who currently have no approved treatment options. We look forward to meeting with the FDA again in the coming months.&#8221;</div>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To date in the Phase 1/2 portion of the trial, six late-stage participants have been treated with OPGx-LCA5, and all six have experienced clinically meaningful
    improvements in vision, providing evidence of biological activity with the potential for functional restoration of vision in individuals with advanced disease.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Opus will incorporate the FDA&#8217;s feedback into its updated clinical development and CMC plans for the Phase 3 portion of the study to include enrolling as few as
    8 participants in a single arm, 12-month study utilizing an adaptive design, which provides flexibility on endpoints and number of participants, reflective of LCA5 as a rare condition with an urgent medical need.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company expects the Phase 3 portion of the trial will include a run-in period prior to dosing to evaluate the natural history of each participant to serve
    as their own control in the study. Opus is actively identifying patients for this segment and has enrolled the first participant. Efficacy and safety will be assessed using measures such as visual acuity, full-field stimulus testing, microperimetry,
    and Multi-Luminance Orientation and Mobility Test (MLoMT). Following availability of validated clinical drug supply manufactured with the intended commercial processes, dosing with OPGx-LCA5 is anticipated in the second half of 2026, with topline
    clinical data expected approximately one year later.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;With recent financing secured, we are strongly positioned to advance our LCA5 program with the rigor and urgency this patient community deserves. As we
    progress into our LCA5 pivotal trial and initiate clinical testing in our second gene therapy program for the treatment of BEST1-related disease, we are entering the next stage of growth as we build the world&#8217;s leading portfolio of gene therapies for
    inherited retinal diseases,&#8221; concluded Dr. Magrath.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2025, the FDA introduced the Rare Disease Evidence Principles (RDEP) review process to facilitate the approval of drugs to treat rare diseases with
    very small patient populations with significant unmet medical need and with a known genetic defect that is the major driver of the pathophysiology. With a patient population of less than 1,000, Opus believes that its LCA5 program meets the eligibility
    criteria for the RDEP process and plans to submit an application.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About OPGx-LCA5</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">OPGx-LCA5 is designed to address a form of Leber congenital amaurosis (LCA) due to biallelic mutations in the LCA5 gene (LCA5), which encodes the lebercilin
    protein. LCA5-associated inherited retinal disease is an early-onset severe inherited retinal dystrophy. Studies in patients with this mutation have reported evidence for the dissociation of retinal architecture and visual function in this disease,
    suggesting an opportunity for therapeutic intervention through gene augmentation. OPGx-LCA5 uses an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5 gene to the outer retina. OPGx-LCA5 is currently being evaluated in a
    Phase 1/2 clinical trial at the University of Pennsylvania. Data from pediatric participants demonstrated large gains in cone-mediated vision, and the therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities. The
    adult cohort showed durable improvements in cone sensitivity and visual function out to 18 months. OPGx-LCA5 has received Rare Pediatric Disease, Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.</div>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Leber Congenital Amaurosis (LCA) and LCA5</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leber congenital amaurosis (LCA) is a group of inherited retinal diseases characterized by severely impaired vision or blindness at birth. Some retinal experts
    consider LCA to be a severe form of retinitis pigmentosa (RP). The condition is caused by degeneration and/or dysfunction of photoreceptors, the cells in the retina that make vision possible. Mutations in one of more than two dozen genes can cause LCA.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">LCA5 is an ultra-rare disease caused by mutations in the LCA5 gene, which encodes lebercilin, a protein essential for photoreceptor structure and function. LCA5
    accounts for roughly 2% of all LCA cases, or approximately 200 patients. There are currently no approved therapies for LCA5-related inherited retinal degeneration, making gene therapy a potentially transformative approach.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Opus Genetics</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule
    therapies for other ophthalmic disorders. The Company&#8217;s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy
    candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a
    partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information,
    visit <font style="color: rgb(70, 120, 133);"><u><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">www.opusgtx.com</font></u></font>.</div>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but
    are not limited to, the clinical development of, and clinical results and future plans for, OPGx-LCA5, potential meetings with the FDA regarding our OPGx-LCA5 program, and expectations regarding us, our business prospects, and our results of operations
    and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that
    could cause or contribute to such differences include, but are not limited to, those described under the heading &#8220;Risk Factors&#8221; included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our other filings with the
    U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current
    expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and
    uncertainties. In some cases, you can identify forward-looking statements by the following words: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;aim,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
    &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or
    circumstances that might subsequently arise.</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contacts:</div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Investors</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Jenny Kobin</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Remy Bernarda</div>
  <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">IR Advisory Solutions</div>
  <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);"><font style="color: rgb(70, 120, 133);"><u>ir@opusgtx.com</u></font><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Media</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Kimberly Ha</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">KKH Advisors</div>
  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">917-291-5744</div>
  <div style="text-align: left; color: #467886; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>kimberly.ha@kkhadvisors.com</u></div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">4</font>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ird-20251106.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<xs:schema targetNamespace="http://opusgtx.com/20251106" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ird="http://opusgtx.com/20251106" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ird-20251106_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ird-20251106_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://opusgtx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ird-20251106_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ird-20251106_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://opusgtx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ird-20251106.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://opusgtx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  06,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Opus Genetics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001228627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3516358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8 Davis Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">957-9024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IRD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ny20058362x4_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://opusgtx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ird-20251106.xsd</File>
    <File>ird-20251106_lab.xml</File>
    <File>ird-20251106_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ny20058362x4_8k.htm">ny20058362x4_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ny20058362x4_8k.htm": {
   "nsprefix": "ird",
   "nsuri": "http://opusgtx.com/20251106",
   "dts": {
    "schema": {
     "local": [
      "ird-20251106.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ird-20251106_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ird-20251106_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ny20058362x4_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://opusgtx.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20251106to20251106",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20058362x4_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251106to20251106",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20058362x4_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://opusgtx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-25-040675-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-040675-xbrl.zip
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M#WO;SXBY9:C4W?Z!QG=4$KEZ4%?.<Y-R!Q#5N$<]VK@V<HP30HFII$ ]!D$
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M&YL'NNNF?02UQW9+H;(@;D*EK1O["Z:Z$:<DP[L.BEC=@&B"(#C+U0YV,\V
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M@F5.P)5BM$A,F^2"F(-=]H[D$2DGG&@O&\,+:T=+#L(2;YN^[;P)8N_LHY-
MD"[Y-!<EV:V_<PIN@A<EX3<8] IYF[-W>P_+ZH5T-4?* ;6$=A Y;N@['A\.
M02--TPLCYII#%@P-.K2,+81V(2QC,'LWA2<F"$*7T5EW!E!W(;[</\MO>!J
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M$VF"S;O.;KB=)NBQKU+_>"+O. _I5,K#!21-TW5M7M(^Z/0(*/'$N<ZWG^"
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ML[$*(A3CI9R!:ZR[:U:@KW\B26&K>W:7(*6RDP_-8$U8N-RH\BT/"LA5&C(
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MS<2FG^2;-PB9W!N<^?* 6B*H86NOP>T>CK"NA*K\G')N@EP&R\J9!$.^.5X
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MM\3?9\Z%&^^Z[]WW\'*QEF_,:E@YA8VFZ 2+2'S* 0LVM>72TDI=B1;9.D\
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M ?<[3#EQA<,F)UY/59A!^A0#^'A-+)*H EX$,UI4<T_]I[5.G;>"^Z=Q$Z=
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M2P$"% ,4    "  Q0V9;3KA9,GL(   Q5@  %               @ %R P
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I,#4X,S8R>#1?97@Y.2TR+FAT;5!+!08     !@ & (T!  !140     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ny20058362x4_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ird-20251106.xsd" xlink:type="simple"/>
    <context id="c20251106to20251106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <startDate>2025-11-06</startDate>
            <endDate>2025-11-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20251106to20251106"
      id="Fact_3e7c73bae3b1489fb51668a095f5478b">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20251106to20251106"
      id="Fact_3215b7ca6c38423caa07ebc5c88b135d">0001228627</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20251106to20251106"
      id="Fact_7cc84b12df5a4adaa324db56a05fc359">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20251106to20251106"
      id="Fact_be0e0839da414ddf904016b5277f2d76">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20251106to20251106"
      id="Fact_5f47c948e66549118cfd716db60a6206">2025-11-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20251106to20251106"
      id="Fact_f5789a09ced34601a2b51402b10275f8">Opus Genetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20251106to20251106"
      id="Fact_d891607bb9364933a887f8861733eebc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20251106to20251106"
      id="Fact_aca7f8db8a3748b89b592c6be1cf3b52">001-34079</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20251106to20251106"
      id="Fact_946799eb84384ab29c72baf0210f20b3">11-3516358</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20251106to20251106"
      id="Fact_00cfb7a941b042308c064a65597562e1">8 Davis Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20251106to20251106"
      id="Fact_9b81b1e629a44e488a1227e728c2fec9">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20251106to20251106"
      id="Fact_b76bd224cd1c4a458dfefb002a1b4879">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20251106to20251106"
      id="Fact_df8dee08f58048ba92b15d95b11a8cb0">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20251106to20251106"
      id="Fact_f6f0a65daf6d4c8ab62de7a302dfafeb">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20251106to20251106"
      id="Fact_afb9c2a127b94d76a54e386a79a8f644">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20251106to20251106"
      id="Fact_9678e496698342cca655d4a36e9a2859">957-9024</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20251106to20251106"
      id="Fact_174ce4d8e1be44aab65de116328e93bc">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20251106to20251106"
      id="Fact_2aa9ece918464f82a931fede3c5517af">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20251106to20251106"
      id="Fact_6b48ce8639734d66afc14022ec875b8b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20251106to20251106"
      id="Fact_5e5a3cfdeb354968b1cb719b9b987f77">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20251106to20251106"
      id="Fact_612bdfb951274f06af3038330de37992">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20251106to20251106"
      id="Fact_4a0c6dc3ecda43989bed020313b8e665">IRD</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20251106to20251106"
      id="Fact_87d3f6b5bd1044a190584812a8d359cd">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
